Prostate Cancer Therapeutics Market By Drug Class (Chemotherapeutic agents, Immune System Modulators, Hormones, Others), By Route Of Administration (Oral, Parenteral, Other), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others), and Geography 


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Prostate Cancer Therapeutics Market size was valued at USD 11.14 billion in 2021, growing at a CAGR of 6.6% during the forecast period 2022-2028. The prostate is an exocrine gland and found only in males.  Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It may spread to other parts of the body mainly bones and lymph nodes. Prostate cancer is the most common type of cancer among men, but often it can be treated successfully, in initial stages it shows no symptoms but later stages it may produce pain in pelvis, difficulty in urination and furthermore, it may cause tiredness and low levels of RBC. The exact cause of prostate cancer is unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer. Primary risk factors for prostate cancer include obesity, age and family history. Prostate cancer can be diagnosed by biopsy, prostate imaging and various other techniques. New tests such as phi test, 4Kscore test, Progensa, TMPRSS2 ERG and ConfirmMDX will be more accurate in early-stage diagnosis. This, in turn, aids in increasing the diagnosis rate and consecutively aid in the growth of the market. Prostate cancer therapeutics market has large and small players and the market is highly competitive. Players adopting acquisitions, mergers and collaborations to stenghten product offerings in prostate therapeutics market.

Key Developments: On September 17, 2019 FDA approved Apalutamide (ERLEADA, Janssen Biotech, Inc) for metastatic castration – sensitive prostate cancer (mCSPC) In 2016, October, U.S. FDA approved a supplemental new drug application for XTANDI (enzalutamide) capsules of Astellas Pharma Inc. & Pfizer Inc. to treat patients with metastatic xastration resistance prostate cancer In 2011, Johnson & Johnson has received U.S. FDA approval for ZytIGA used to treat metastatic prostate cancer.

Global Prostate Cancer Therapeutics Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

–  Asia Pacific
Prostate Cancer Therapeutics Market Dynamics

prostate cancer therapeutics market is rapidly growing due to increase in incidence of prostate cancer and increase in ageing population. In addition, technological advancements in prostate cancer treatment such as radiation therapy and targeted therapy are expected to boost the prostate cancer therapeutics market. However, patients in underdeveloped and developing regions cannot afford the high costs of treatment and diagnosis of cancer can hinder market growth. In addition to this, low diagnostic rates due to unawareness about prostate cancer symptoms is hampering the prostate cancer therapeutics market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Prostate Cancer Therapeutics Market Segmentation

drug class
  • Chemotherapeutic agents
  • Immune System Modulators
  • Hormones
  • Others
  • Oral
  • Parenteral
  • Other
Distribution Channel
  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

Frequently Asked Questions

The prostate cancer therapeutics market is projected to expand at a CAGR of 6.6% during the forecast period

Johnson & Johnson Services Inc. (U.S.), AbbVie, Inc.(U.S.), Amgen, Inc.(U.S.), AstraZeneca (U.K), Ipsen Group(France), Sanofi (France)

North America is the fastest-growing region for prostate cancer therapeutics market

[urltag url='request-table-of-content']

  • Johnson & Johnson Services Inc. (U.S.)
  • AbbVie, Inc.(U.S.)
  • Amgen, Inc.(U.S.)
  • AstraZeneca (U.K)
  • Ipsen Group(France)
  • Sanofi (France)
  • Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S.)
  • Bayer AG (Germany)
  • Endo Pharmaceuticals, Inc. (U.S)
  • Pfizer, Inc (U.S.)